NCT01630018
Completed
Phase 2
A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer
Overview
- Phase
- Phase 2
- Intervention
- Topotecan
- Conditions
- Epithelial Ovarian Cancer
- Sponsor
- Chong Kun Dang Pharmaceutical
- Enrollment
- 141
- Locations
- 1
- Primary Endpoint
- Objective response rate
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).
Detailed Description
A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan (CamtoBell inj.) or Topotecan in Patients with Recurrent or Refractory Ovarian Cancer
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least 18 years of age
- •Histological or cytological diagnosis of AOC
- •Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC ≥ 90 days of duration of response for first-line therapy
- •Measurable disease defined by RECIST criteria
- •ECOG Performance Status of 0, 1, or 2
- •Life expectancy \> 3 months
- •Adequate bone marrow, Renal, Hepatic reserve:
- •absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL
- •platelet count ≥ 100,000 cells/μL
- •hemoglobin ≥ 9 g/dL
Exclusion Criteria
- •Active infection
- •Symptomatic brain lesion
- •Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases
- •Prior anticancer therapy within 4 weeks before enroll
- •Active pregnancy test and Pregnant or nursing women
- •Participation in any investigational drug study within 28 days prior to study entry
Arms & Interventions
Topotecan
Topotecan
Intervention: Topotecan
Camtobell
Belotecan
Intervention: Belotecan
Outcomes
Primary Outcomes
Objective response rate
Time Frame: approximately 21 days(every 1 Cycle)
Secondary Outcomes
- Overall Survival(up to 4 years)
- Progression Free survival(up tp 4 years)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung CancerSmall Cell Lung CancerNCT01497873Chong Kun Dang Pharmaceutical164
Completed
Phase 2
Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancerJPRN-C000000130Okayama Lung Cancer Study Group30
Completed
Phase 2
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27
Completed
Phase 2
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerPeritoneal CancerOvarian CancerNeoplasms, OvarianFallopian Tube CancerNCT00061308GlaxoSmithKline75
Active, not recruiting
Phase 2
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAtypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaMyelodysplastic/Myeloproliferative NeoplasmMyelofibrosisPolycythemia VeraRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT03289910National Cancer Institute (NCI)25